Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today ...
Pyxis Oncology (NASDAQ:PYXS), a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment, has been garnering attention from investors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results